Zhang Z, et al. - With the intention of preventing chemotherapy-induced nausea and vomiting, experts comparatively analyzed the antiemetic effects of olanzapine-based triplet and neurokinin-1 receptor antagonists (NK-1RAs)-based triplet regimen. With regard to nausea control and drug price, olanzapine-based triplet was found to be superior but represented no notable variation of complete responses (CRs) in comparison with NK-1RAs-based triplet. Findings recommended that Olanzapine-based triple regimens ought to be used as an optional antiemetic choice for patients with highly emetogenic chemotherapy (HEC), particularly those suffering from delayed phase nausea.